“Two-phase”的搜索结果，显示 121-130 项，共有 4339 项

1. 放射科- 临床试验- 妙佑医疗国际

   ... 2 participants will also undergo MRI scanning ... ADPKD is a leading cause of end-stage renal disease. ... ADPKD is a leading cause of end-stage renal disease.

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. ... (2) Cohort 2 focuses on primary or ...

3. 乳腺专科门诊- 临床试验- 妙佑医疗国际

   This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/ ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... Phase 2 part to further assess the effectiveness and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess ...

5. 神经科- 临床试验- 妙佑医疗国际

   The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with ...

6. 妇产科- 临床试验- 妙佑医疗国际

   ... phase 2 dose (RP2D) 1.1.2 To evaluate the safety and tolerability of this combination in a dose expansion cohort in patients with uterine serous carcinoma.

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   Rochester, Minn. This is a randomized Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric ...

8. 血液科- 临床试验- 妙佑医疗国际

   This study includes 2 parts; step-up dose optimization (Part 1) and dose ... phase II dose (RP2D of APG2575 in combination with Pomalidomide ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... phase. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) ... two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module ...

10. 乳腺专科门诊- 临床试验- 妙佑医疗国际

    This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/ ...